You are here
Anixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology
SAN JOSE, Calif., July 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,360,499, a key component of Anixa's Cchek™ technology for early detection of cancer.
This patent provides broader coverage for the use of Anixa's technology in a wider range of applications and protects critical new improvements developed for Anixa's cancer detection technology, utilizing flow cytometry and artificial intelligence.
"The claims of this patent were allowed in March of this year as noted in a previous announcement, and we are pleased that this key patent has finally been issued," stated Dr. Amit Kumar, President and CEO of Anixa. "We are pleased to receive further patent protection on our liquid biopsy technology and look forward to launching a prostate cancer confirmatory test as the first product utilizing this technology later this year."
The patent is titled, "METHODS FOR USING ARTIFICIAL NEURAL NETWORK ANALYSIS ON FLOW CYTOMETRY DATA FOR CANCER DIAGNOSIS." Inventors of the patent include Dr. Amit Kumar, John Roop, Anthony Campisi, and Dr. George Dominguez. This patent is held exclusively by Anixa and is not licensed to any third parties.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixa's diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Sharen Tilman (Investors)
Johanna Bennett (Media)
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-additional-patent-issued-on-cancer-detection-technology-300889896.html
SOURCE Anixa Biosciences, Inc.